CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

清淋前淋巴细胞/单核细胞与乳酸脱氢酶比值影响接受 CAR-T 细胞治疗的弥漫大 B 细胞淋巴瘤患者结局

英文原题：Lymphocyte/monocyte to lactate dehydrogenase ratio prior to lymphodepletion impact the outcomes of patients with diffused large B cell lymphoma undergoing CAR-T cell therapy.

查看英文原题

Lymphocyte/monocyte to lactate dehydrogenase ratio prior to lymphodepletion impact the outcomes of patients with diffused large B cell lymphoma undergoing CAR-T cell therapy.

PubMed 2025/03/15（内容时间） Cancer Immunol Immunother Q1 · IF 5.8（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

技术：CAR-T弥漫大B细胞淋巴瘤淋巴瘤地区：中国
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

中文摘要

复发/难治性（R/R）弥漫大B细胞淋巴瘤（DLBCL）患者接受嵌合抗原受体（CAR）-T细胞治疗后的结局相关因素尚未完全阐明。

我们探讨了淋巴细胞清除前（pre-LD）淋巴细胞与单核细胞比值（LMR）及其与乳酸脱氢酶（LDH）的比值（LMR/LDH）对60例接受CAR-T 细胞治疗的R/R DLBCL患者疗效和预后的影响。pre-LD LMR和LMR/LDH的最佳截断值分别为3.583和0.0103。高pre-LD LMR或LMR/LDH患者的总体缓解率（ORR）高于低pre-LD LMR或LMR/LDH患者（ORR分别为100% vs. 65.79%，P = 0.006和96.15% vs. 38.24%，P < 0.0001）。多因素logistic回归分析显示，pre-LD LMR/LDH是与ORR相关的独立因素（P = 0.010，比值比 = 18.757；95%置信区间[CI] 2.046-171.975）。

高pre-LD LMR/LDH患者的无进展生存期（PFS）（中位PFS，29.73 vs. 2.47个月，P < 0.0001）和总生存期（OS）（中位OS，未达到 vs. 7.4个月，P = 0.0002）显著长于低pre-LD LMR/LDH患者。多因素Cox回归分析显示，pre-LD LMR/LDH和ORR是影响PFS的独立因素（分别为P = 0.030，风险比[HR] = 2.561；95% CI 1.093-5.999和P = 0.024，HR = 2.202；95% CI 1.22-4.369）；pre-LD LMR/LDH是影响OS的独立因素（P = 0.029，HR = 3.331；95% CI 1.131-9.807）。

总之，pre-LD LMR/LDH是与接受CAR-T 细胞治疗的R/R DLBCL患者ORR相关的独立因素，也是独立的预后因素。

展开英文摘要原文

Factors associated with outcomes of chimeric antigen receptor (CAR)-T cell therapy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have not been fully elucidated.

We explored the impact of the prelymphodepletion (pre-LD) lymphocyte to monocyte ratio (LMR) and its ratio to lactate dehydrogenase (LDH) (LMR/LDH) on the efficacy and prognosis of 60 patients with R/R DLBCL undergoing CAR-T cell therapy. The optimal cutoff values for pre-LD LMR and LMR/LDH were 3. 583 and 0. 0103, respectively. The overall response rate (ORR)s were higher in patients with high pre-LD LMR or LMR/LDH than those with low pre-LD LMR or LMR/LDH (ORR, 100% vs. 65. 79%, P = 0. 006 and 96. 15% vs. 38. 24%, P < 0. 0001, respectively). Pre-LD LMR/LDH was an independent factor associated with ORR (P = 0. 010, odds ratio = 18. 757; 95% confidence interval [CI] 2.

046-171. 975) by multivariate logistic regression analysis. Patients with high pre-LD LMR/LDH had significantly longer progression-free survival (PFS) (median PFS, 29. 73 vs. 2. 47 months, P < 0. 0001) and overall survival (OS) (median OS, not reached vs. 7. 4 months, P = 0. 0002) than those with low pre-LD LMR/LDH.

Multivariate Cox regression analysis showed that pre-LD LMR/LDH and ORR were independent factors affecting PFS (P = 0. 030, hazard ratio [HR] = 2. 561; 95% CI 1. 093-5. 999 and P = 0. 024, HR = 2. 202; 95% CI 1. 22-4. 369, respectively); pre-LD LMR/LDH was an independent factor affecting OS (P = 0. 029, HR = 3. 331; 95% CI 1. 131-9. 807).

In conclusion, the pre-LD LMR/LDH was an independent factor associated with ORR and an independent prognostic factor in patients with R/R DLBCL undergoing CAR-T cell therapy.

论文信息

作者
Li N、An N、Ma S、Cao J、Zhu F、Qi K、Yan Z、Cheng H
第一作者单位
Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.China
通讯作者单位
Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. ccwing28@163.com.China
期刊
Cancer immunology, immunotherapy : CII2025 Mar 15
原文标识
PubMed 40088299　·　DOI 10.1007/s00262-025-03987-4

在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →